Mandate

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue

November 12, 2020 Capital Markets and Public M&A

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue was, inter alia, to carry out a capital raise in a timely and cost-effective manner, further diversifying and strengthening Xbrane Biopharma´s shareholder base, as well as finance the continued development of Xbrane Biopharma´s product portfolio, including finalization of development and the regulatory process regarding Xlucane.

Vinge’s team has consisted of Jesper Schönbeck, Linnéa Sellström, Anders Sundin Lundberg and Lisa Malmborg.

Related

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025

Vinge advises The Qt Company Ltd on its public offer for I.A.R. Systems Group AB (publ)

The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share
July 04, 2025

Vinge has advised Consolid on the establishment of Consolid Equity III

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025